Leipzig

• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting
  2025-522440-41-00 4 2026-04-27 Hidradenitis Suppurativa
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting
  2025-523657-34-00 5 2026-04-13 Obesity
• Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me … Recruiting
  2025-523263-37-00 10 2026-04-08 Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
• A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting
  2025-522578-35-00 4 2026-03-30 Atopic Dermatitis
• Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met … Recruiting
  2025-523224-45-00 10 2026-03-30 Untreated, Unresectable or Metastatic Colorectal Cancer
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin … Recruiting
  2024-518210-81-00 5 2026-03-18 Advanced Hepatocellular Carcinoma
• A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting
  2025-522642-44-00 4 2026-03-18 CHRONIC SPONTANEOUS URTICARIA
• Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting
  2025-521416-19-00 4 2026-03-12 Recurrence of Clostridioides difficile Infection
• Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants Recruiting
  2025-521762-99-00 5 2026-03-09 acute ischemic stroke
• A trial to learn how well AZD4144 works, how safe it is, and how it moves throughout the body over time in adults with acute kidney injury c … Recruiting
  2025-522232-13-00 4 2026-03-06 Sepsis-associated acute kidney injury (AKI)
• An Open-Label Extension, Multi-Centered, Phase 2 Trial of TEV-56286 (Emrusolmin) for Multiple System Atrophy Recruiting
  2025-521642-14-00 4 2026-03-05 Multiple System Atrophy
• Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting
  2025-521670-34-00 5 2026-03-04 Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
• A trial to evaluate the efficacy and safety of oral controlled-ileal-release nicotinic acid (CIR-NA) for inducing remission in subjects with … Recruiting
  2024-519903-88-00 4 2026-03-03 Prediabetes
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting
  2024-516411-24-00 5 2026-02-25 Insomnia Disorder
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host … Recruiting
  2025-521849-25-00 4 2026-02-17 Chronic Graft-Versus-Host Disease
• A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma Recruiting
  2025-522640-41-00 4 2026-02-13 Asthma
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)

Showing 121–144 of 720 trials